Seiichi Imanishi

Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer

Katsuhiko Nakatsukasa, Hiroshi Koyama, Yoshimi Oouchi et al. · Breast Cancer · 2016 · 48 citations

Medicine, Oncology, Pharmacology +14

Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC

Seiichi Imanishi, Yasuto Naoi, Kenzo Shimazu et al. · Breast Cancer Research and Treatment · 2019 · 25 citations

Medicine, Cancer Biology, Oncology +16

Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer

Nabeel Kajihara, Takuto Kobayashi, Ryo Otsuka et al. · Cancer Immunology Immunotherapy · 2022 · 24 citations · Full text

Medicine, Immunology, Oncology +17

Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer

Katsuhiko Nakatsukasa, Hiroshi Koyama, Yoshimi Oouchi et al. · Breast Cancer · 2016 · 12 citations

Medicine, Oncology, Pharmacology +14